collection
MENU ▼
Read by QxMD icon Read
search

Anticoagulation 2015

shared collection
17 papers 25 to 100 followers
By EFRAIN PAEZ Internal Medicine since 1988. Interested in all aspects of Medicine.
https://www.readbyqxmd.com/read/26417060/stent-thrombosis-and-restenosis-what-have-we-learned-and-where-are-we-going-the-andreas-gr%C3%A3-ntzig-lecture-esc-2014
#1
REVIEW
Robert A Byrne, Michael Joner, Adnan Kastrati
Modern-day stenting procedures leverage advances in pharmacotherapy and device innovation. Patients treated with contemporary antiplatelet agents, peri-procedural antithrombin therapy and new-generation drug-eluting stents (DES) have excellent outcomes over the short to medium term. Indeed, coupled with the reducing costs of these devices in most countries there remain very few indications where patients should be denied treatment with standard-of-care DES therapy. The two major causes of stent failure are stent thrombosis (ST) and in-stent restenosis (ISR)...
December 14, 2015: European Heart Journal
https://www.readbyqxmd.com/read/26343041/decision-making-about-the-use-of-non-vitamin-k-oral-anticoagulant-therapies-for-patients-with-atrial-fibrillation
#2
Mark H Eckman
Until recently, vitamin K antagonists, warfarin being the most commonly used agent in the United States, have been the only oral anticoagulant therapies available to prevent stroke in patients with atrial fibrillation (AF). In the last 5 years four new, non-vitamin K oral anticoagulants, the so-called NOACs or novel oral anticoagulants, have come to market and been approved by the Federal Drug Administration. Despite comparable if not superior efficacy in preventing AF-related stroke, and generally lower risks of major hemorrhage, particularly intracranial bleeding, the uptake of these agents has been slow...
February 2016: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/26324838/updated-european-heart-rhythm-association-practical-guide-on-the-use-of-non-vitamin-k-antagonist-anticoagulants-in-patients-with-non-valvular-atrial-fibrillation
#3
Hein Heidbuchel, Peter Verhamme, Marco Alings, Matthias Antz, Hans-Christoph Diener, Werner Hacke, Jonas Oldgren, Peter Sinnaeve, A John Camm, Paulus Kirchhof
The current manuscript is an update of the original Practical Guide, published in June 2013[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51; Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary...
October 2015: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/25638783/dilemmas-in-the-use-of-new-oral-anticoagulants
#4
J Thachil
No abstract text is available yet for this article.
September 2015: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/26199338/comparison-of-the-short-term-risk-of-bleeding-and-arterial-thromboembolic-events-in-nonvalvular-atrial-fibrillation-patients-newly-treated-with-dabigatran-or-rivaroxaban-versus-vitamin-k-antagonists-a-french-nationwide-propensity-matched-cohort-study
#5
MULTICENTER STUDY
Géric Maura, Pierre-Olivier Blotière, Kim Bouillon, Cécile Billionnet, Philippe Ricordeau, François Alla, Mahmoud Zureik
BACKGROUND: The safety and effectiveness of non-vitamin K antagonist (VKA) oral anticoagulants, dabigatran or rivaroxaban, were compared with VKA in anticoagulant-naive patients with nonvalvular atrial fibrillation during the early phase of anticoagulant therapy. METHODS AND RESULTS: With the use of the French medico-administrative databases (SNIIRAM and PMSI), this nationwide cohort study included patients with nonvalvular atrial fibrillation who initiated dabigatran or rivaroxaban between July and November 2012 or VKA between July and November 2011...
September 29, 2015: Circulation
https://www.readbyqxmd.com/read/26163482/antithrombotic-therapy-in-the-elderly-expert-position-paper-of-the-european-society-of-cardiology-working-group-on-thrombosis
#6
REVIEW
Felicita Andreotti, Bianca Rocca, Steen Husted, Ramzi A Ajjan, Jurrien ten Berg, Marco Cattaneo, Jean-Philippe Collet, Raffaele De Caterina, Keith A A Fox, Sigrun Halvorsen, Kurt Huber, Elaine M Hylek, Gregory Y H Lip, Gilles Montalescot, Joao Morais, Carlo Patrono, Freek W A Verheugt, Lars Wallentin, Thomas W Weiss, Robert F Storey
No abstract text is available yet for this article.
December 7, 2015: European Heart Journal
https://www.readbyqxmd.com/read/26121536/how-to-monitor-patients-receiving-direct-oral-anticoagulants-for-stroke-prevention-in-atrial-fibrillation-a-practice-tool-endorsed-by-thrombosis-canada-the-canadian-stroke-consortium-the-canadian-cardiovascular-pharmacists-network-and-the-canadian-cardiovascular
#7
David J Gladstone, William H Geerts, James Douketis, Noah Ivers, Jeff S Healey, Kori Leblanc
No abstract text is available yet for this article.
September 1, 2015: Annals of Internal Medicine
https://www.readbyqxmd.com/read/26151285/jama-patient-page-treatment-duration-for-pulmonary-embolism
#8
Jill Jin
No abstract text is available yet for this article.
July 7, 2015: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/26101510/analysis-of-deep-venous-thrombosis-after-gynecological-surgery-a-clinical-study-of-498-cases
#9
Lihua Zhang, Xiancui Liu, Yunxia Xue
OBJECTIVES: To find out the clinical characteristics and risk factors for deep venous thrombosis (DVT) after gynecological surgery. METHODS: Four hundred and ninety-eight patients treated surgically in the department of gynecology of our hospital from July 2012 to May 2014 were reviewed retrospectively. The data including patient age, gender, medical history, hospital stay, anesthesia type, operation time, occupation type, operative or postoperative medicine, perioperative bleeding, postoperative activity time, mortality rate and so on, were collected...
March 2015: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/26095867/perioperative-bridging-anticoagulation-in-patients-with-atrial-fibrillation
#10
RANDOMIZED CONTROLLED TRIAL
James D Douketis, Alex C Spyropoulos, Scott Kaatz, Richard C Becker, Joseph A Caprini, Andrew S Dunn, David A Garcia, Alan Jacobson, Amir K Jaffer, David F Kong, Sam Schulman, Alexander G G Turpie, Vic Hasselblad, Thomas L Ortel
BACKGROUND: It is uncertain whether bridging anticoagulation is necessary for patients with atrial fibrillation who need an interruption in warfarin treatment for an elective operation or other elective invasive procedure. We hypothesized that forgoing bridging anticoagulation would be noninferior to bridging with low-molecular-weight heparin for the prevention of perioperative arterial thromboembolism and would be superior to bridging with respect to major bleeding. METHODS: We performed a randomized, double-blind, placebo-controlled trial in which, after perioperative interruption of warfarin therapy, patients were randomly assigned to receive bridging anticoagulation therapy with low-molecular-weight heparin (100 IU of dalteparin per kilogram of body weight) or matching placebo administered subcutaneously twice daily, from 3 days before the procedure until 24 hours before the procedure and then for 5 to 10 days after the procedure...
August 27, 2015: New England Journal of Medicine
https://www.readbyqxmd.com/read/26010647/jama-patient-page-deep-vein-thrombosis
#11
Amy E Thompson
No abstract text is available yet for this article.
May 26, 2015: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/26005909/longer-versus-shorter-duration-dual-antiplatelet-therapy-after-drug-eluting-stent-placement-a-systematic-review-and-meta-analysis
#12
REVIEW
Frederick A Spencer, Manya Prasad, Per O Vandvik, Devin Chetan, Qi Zhou, Gordon Guyatt
BACKGROUND: The appropriate duration of dual-antiplatelet therapy (DAPT) after drug-eluting stent (DES) placement remains controversial. PURPOSE: To summarize data on clinical outcomes with longer- versus shorter-duration DAPT after DES placement in adults with coronary artery disease. DATA SOURCES: Ovid MEDLINE and EMBASE, 1996 to 27 March 2015, and manual screening of references. STUDY SELECTION: Randomized, controlled trials comparing longer- versus shorter-duration DAPT after DES placement...
July 21, 2015: Annals of Internal Medicine
https://www.readbyqxmd.com/read/25670639/use-of-low-dose-aspirin-as-secondary-prevention-of-atherosclerotic-cardiovascular-disease-in-us-adults-from-the-national-health-interview-survey-2012
#13
RANDOMIZED CONTROLLED TRIAL
Jing Fang, Mary G George, Renee M Gindi, Yuling Hong, Quanhe Yang, Carma Ayala, Brian W Ward, Fleetwood Loustalot
Current guidelines recommend that adults with atherosclerotic cardiovascular disease take low-dose aspirin or other antiplatelet medications as secondary prevention of recurrent cardiovascular events. Yet, no national level assessment of low-dose aspirin use for secondary prevention of cardiovascular disease has been reported in a community-based population. Using data from the 2012 National Health Interview Survey, we assessed low-dose aspirin use in those with atherosclerotic cardiovascular disease. We estimated the prevalence ratios of low-dose aspirin use, adjusting for sociodemographic status, health insurance, and cardiovascular risk factors...
April 1, 2015: American Journal of Cardiology
https://www.readbyqxmd.com/read/25634169/efficacy-and-safety-of-oral-anticoagulants-versus-aspirin-for-patients-with-atrial-fibrillation-a-meta-analysis
#14
REVIEW
Jing-Tao Zhang, Ke-Ping Chen, Shu Zhang
The purpose of this study was to perform a meta-analysis comparing the effectiveness and safety of anticoagulation to antiplatelet therapy for the prevention of thromboembolic events in patients with atrial fibrillation (AF). MEDLINE, Cochrane, EMBASE, and Google Scholar databases were searched for studies published through May 31, 2014. Randomized controlled trials comparing anticoagulants (warfarin) and antiplatelet therapy in patients with AF were included. The primary outcomes were the rates of stroke and systemic embolism...
January 2015: Medicine (Baltimore)
https://www.readbyqxmd.com/read/25620711/embolic-stroke-during-apixaban-therapy-for-left-atrial-appendage-thrombus
#15
Masaki Ohyagi, Kazuha Nakamura, Mutsufusa Watanabe, Hiroto Fujigasaki
Left atrial appendage (LAA) thrombus is associated with atrial fibrillation (AF) and is a powerful predictor of cardiogenic thromboembolism. Warfarin is an established anticoagulant therapy for patients with LAA thrombus to prevent thromboembolic complications. Apixaban is superior to warfarin in the prevention of thromboembolic complications in patients with AF, and there are case reports showing apixaban-associated resolution of LAA thrombus; however, the efficacy and safety of apixaban for the treatment of LAA thrombus remains unproven...
April 2015: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://www.readbyqxmd.com/read/25619266/acute-pulmonary-embolism-risk-assessment-risk-stratification-and-treatment-options
#16
REVIEW
Franco Piovella, Diana Irina Iosub
INTRODUCTION: Pulmonary embolism (PE) is a potentially life-threatening cardiovascular emergency with a high mortality rate. Rapid diagnosis and treatment are important in optimising clinical outcomes in patients with PE, and anticoagulants are the mainstay of treatment. Traditionally, anticoagulant therapy involves parenteral anticoagulants, overlapping with and followed by oral vitamin K antagonists. Direct oral anticoagulants (DOACs), including the factor Xa inhibitors rivaroxaban, apixaban and edoxaban, and the direct thrombin inhibitor dabigatran etexilate, have been developed to address limitations associated with traditional anticoagulant therapy...
September 2016: Clinical Respiratory Journal
https://www.readbyqxmd.com/read/25677422/should-atrial-fibrillation-patients-with-1-additional-risk-factor-of-the-cha2ds2-vasc-score-beyond-sex-receive-oral-anticoagulation
#17
Tze-Fan Chao, Chia-Jen Liu, Kang-Ling Wang, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Ta-Chuan Tuan, Tzeng-Ji Chen, Gregory Y H Lip, Shih-Ann Chen
BACKGROUND: Although the CHA2DS2-VASc (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female) score is recommended by both American and European guidelines for stroke risk stratification in atrial fibrillation (AF), the treatment recommendations for a CHA2DS2-VASc score of 1 are less clear. OBJECTIVES: This study aimed to investigate the risk of ischemic stroke in patients with a single additional stroke risk factor (i...
February 24, 2015: Journal of the American College of Cardiology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"